{rfName}
Fa

Indexed in

License and use

Icono OpenAccess

Citations

10

Altmetrics

Analysis of institutional authors

Menendez, JaCorresponding AuthorLopez, JAuthorMartin-Castillo, BAuthor

Share

May 27, 2024
Publications
>
Article
Sí

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

Publicated to:Molecular Oncology. 18 (3): 479-516 - 2024-03-01 18(3), DOI: 10.1002/1878-0261.13582

Authors: Menendez, JA; Cuyàs, E; Encinar, JA; Vander Steen, T; Verdura, S; Llop-Hernández, A; López, J; Serrano-Hervás, E; Osuna, S; Martin-Castillo, B; Lupu, R

Affiliations

Catalan Inst Oncol, Unit Clin Res - Author
Girona Biomed Res Inst - Author
ICREA - Author
Mayo Clin Lab, Mol Biol Lab - Author
Mayo Clin, Canc Ctr, 200 First St SW - Author
Mayo Clin, Canc Ctr, Biochem & Mol Biol, Expt Pathol & Med,Coll Med, 200 First St SW - Author
Miguel Hernandez Univ UMH, Mol & Cell Biol Inst IBMC - Author
Univ Girona, Dept Quim - Author
See more

Abstract

The initial excitement generated more than two decades ago by the discovery of drugs targeting fatty acid synthase (FASN)-catalyzed de novo lipogenesis for cancer therapy was short-lived. However, the advent of the first clinical-grade FASN inhibitor (TVB-2640; denifanstat), which is currently being studied in various phase II trials, and the exciting advances in understanding the FASN signalome are fueling a renewed interest in FASN-targeted strategies for the treatment and prevention of cancer. Here, we provide a detailed overview of how FASN can drive phenotypic plasticity and cell fate decisions, mitochondrial regulation of cell death, immune escape and organ-specific metastatic potential. We then present a variety of FASN-targeted therapeutic approaches that address the major challenges facing FASN therapy. These include limitations of current FASN inhibitors and the lack of precision tools to maximize the therapeutic potential of FASN inhibitors in the clinic. Rethinking the role of FASN as a signal transducer in cancer pathogenesis may provide molecularly driven strategies to optimize FASN as a long-awaited target for cancer therapeutics.

Keywords

Antigenic escapeApoptosisArticleBeta-ketoacyl reductaseBrain metastasisBreast-cancerCancer stem cellCancer-cell growthCarcinogenesisCell agingCell deathCell dedifferentiationCell fateCell line, tumorCell stemnessCell transdifferentiationDe-novo lipogenesisDiet therapyDifferentiation therapyDormancyDrug targetingEnzyme activationEnzyme inhibitionEpithelial-mesenchymal transitionFasn protein, humanFatty acid synthaseFatty acid synthase inhibitorFatty acid synthase, type iFatty acid synthasesFerroptosisGeneticsHepatocellular-carcinomaHumanHumansImmune checkpoint proteinImmune responseImmunotherapyLipidLipid transportLipid-metabolismLipogenesisMalignant neoplasmMetabolismMetastasisMetastasis potentialMitochondrial metabolismMitochondrial primingMitochondrionMolecular gluesNeoplasmNeoplasmsNonhumanNuclear reprogrammingPalmitoylationPersonalized cancer therapyPersonalized medicinePhenotypic plasticityPrecision medicineProtein degradationProtein protein interactionSenescence inductionSignal transductionT cell dysfunctionTumor cell lineTumor immunityTumor microenvironmentUbiquitin protein ligase e3Vulnerability

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Molecular Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 67/322, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-06:

  • WoS: 3
  • Scopus: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 55.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 55 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.45.
  • The number of mentions on the social network X (formerly Twitter): 10 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Menendez Menendez, Javier Abel) .

the author responsible for correspondence tasks has been Menendez Menendez, Javier Abel.